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Endothelial cells line the inner portion of the heart,
blood vessels, and lymphatic vessels; a basal membrane
of extracellular matrix lines the extraluminal side of
endothelial cells. The apical side of endothelial cells is
the site for the glycocalyx, which is a complex network
of macromolecules, including cell-bound proteoglycans
and sialoproteins. Sepsis-associated alterations of this
structure may compromise endothelial permeability
with associated interstitial fluid shift and generalized
edema. Indeed, in sepsis, the glycocalyx acts as a target
for inflammatory mediators and leukocytes, and its
ubiquitous nature explains the damage of tissues
that occurs distant from the original site of infection.
Inflammatory-mediated injury to glycocalyx can be
responsible for a number of specific clinical effects
of sepsis, including acute kidney injury, respiratory
failure, and hepatic dysfunction. Moreover, some
markers of glycocalyx degradation, such as circulating
levels of syndecan or selectins, may be used as markers
of endothelial dysfunction and sepsis severity. Although
a great deal of experimental evidence shows that
alteration of glycocalyx is widely involved in endothelial
damage caused by sepsis, therapeutic strategies aiming
at preserving its integrity did not significantly improve
the outcome of these patients.matrix of the basal membrane. Soluble components - thatIntroduction
Sepsis is the clinical syndrome of a systemic response
to microbial infections. During septic shock, mortality
can peak at 56% [1,2]. Sepsis is associated with altered
micro-hemodynamics and heterogeneous local perfusion,
micro-thrombosis and endothelial dysfunction, alteration
of permeability, and interstitial fluid shift [3-6]. The endo-
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unless otherwise stated.involved in many endothelial functions [7]. Sepsis leads to
ubiquitous degradation of the glycocalyx, altered endothe-
lial permeability with hypovolemia, hypoalbuminemia,
and edema [8,9]. This review focuses on the role of glyco-
calyx during sepsis.
Structure of endothelial barrier
Endothelial cells line in a single layer along the inner
portion of the heart, blood vessels, and lymphatic ves-
sels. They derive from angioblasts and hemangioblasts
and thus are sensitive to the mediators of angiogenesis
such as vascular endothelial growth factor (VEGF) [10].
The space between two contiguous endothelial cells is
called the endothelial cleft (ETC), which acts as an im-
portant site of regulation of endothelial permeability (that
is, paracellular permeability) [11]. The apical side of endo-
thelial cells is layered by the glycocalyx, which is 1 to
3 μm in depth (Figure 1). Synthesis of glycocalyx is com-
plex, involving multiple enzymatic pathways; factors regu-
lating its shedding include local pH and mechanical
stimuli [12]. Components of glycocalyx include cell-bound
proteoglycans, glycosaminoglycan (GAG) side chains, and
sialoproteins [4,8,13]. Proteoglycans consist of a core
protein to which GAGs are linked. Core proteins include
syndecans, glypicans, and perlecans. This complex net-
work envelops endothelial cells on their luminal side and
inside the clefts, where it continues into the extracellular
is, albumin, unbound hyaluronic acid molecules, throm-
bomodulin, and various serum proteins (for example,
superoxide dismutase, antithrombin III, and cell adhesion
molecules) - are bound to the luminal portions of glycoca-
lyx [4].
Main methods for studying/visualizing glycocalyx
Owing to its fragility and instability, endothelial glycocalyx
has been particularly difficult to characterize and under-
stand in its three-dimensional structure [14]. Transmis-
sion electron microscopy (TEM), the original method of
visualization, has several technical limits and a great deall. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Glycocalyx structure and the glycocalyx-endothelial barrier. ATIII, anti thrombin III; GAG, glycosaminoglycan.
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as substituting the original ruthenium red staining with
Lanthanum or Alcian blue, which allow a better preserva-
tion of glycocalyx. The use of non-aqueous vehicles of per-
fusion is also associated with better preserved samples.
Finally, by observing the glycocalyx on rapidly frozen tis-
sues, the alterations due to organic solvents are avoided. A
major limit of TEM is that it cannot be used in vivo. An-
other method for direct visualization of glycocalyx is based
on fluorescent-labeled ‘lectins’, which are proteins that
specifically bind to some components of glycocalyx, or on
fluorescent-labeled antibodies for heparan sulfate, synde-
cans, or hyaluronan. A semi-quantitative measurement of
fluorescence can be obtained with a confocal laser scan-
ning microscope in small vessels, whereas in larger vessels
two-photon laser scanning microscopy is used because of
its increased depth of penetration into tissue [17].
Among indirect methods, intravital microscopy or intravas-
cular volume determinations with permeable/impermeable
tracers have been used [18,19].
Physiologic role of glycocalyx
The glycocalyx plays a key role in microvascular and
endothelial physiology, in particular by regulating micro-
vascular tone and endothelial permeability, maintaining
an oncotic gradient across the endothelial barrier, regu-
lating adhesion/migration of leukocytes, and inhibiting
intravascular thrombosis [20,21]. The glycocalyx acts as
a ‘mechanotransducer’, transmitting shear stress forces
to endothelial cells through its intracellular protein do-
mains. Conformational changes in glycocalyx structure lead
to release of nitric oxide, thus contributing to regulation of
vasomotor tone and peripheral distribution of blood flow/
oxygen to tissues [15]. Acting through this mechanism,
the glycocalyx contributes to regulation of local blood flow
of organs and acts as an effector of metabolic coupling
between organ function and local hemodynamics. The
glycocalyx is central in maintaining the oncotic gradient
across the endothelial barrier. In the so-called ‘paracellular
permeability model’, fluids and solutes flow from theintravascular to the interstitial space through the glyco-
calyx that surrounds the ETCs and reaches the basal
membrane. Therefore, the oncotic gradient between intra-
vascular and interstitial spaces is set between the plasma
and the glycocalyx rather than being trans-endothelial. In
physiologic conditions, the glycocalyx retains a high re-
flection capability for albumin because of the high density
of negative electric charges of its GAG side chains [22];
thus, albumin is not allowed to flow through the clefts
(Figure 2). About 40% of total human body albumin is
intravascular, whereas only 5% is normally allowed to flow
in the interstitial space. Thus, albumin is the main deter-
minant of intravascular colloid-oncotic pressure (πiv). In
the paracellular permeability model, the ETCs act as the
small pores of the capillaries, through which the transca-
pillary flow of fluid occurs. In the traditional Starling
model, the driving forces for this flow are the intracapillar
hydrostatic pressure (Piv) and the interstitial colloid-
oncotic pressure (πis). Since the inner portion of the ETCs
is covered by the glycocalyx, it was recently proposed that
the sub-glycocalyx colloid-oncotic pressure plays a major
role as a determinant of transcapillary flow [20]. In normal
conditions, this ‘sub-glycocalyx’ space is virtually protein-
free, and the only determinant of the transcapillary flow is
the Piv. The πiv opposes the flux but does not reverse fil-
tration through the endothelial barrier. In normal condi-
tions, only small amounts of fluid are filtered and most of
it returns to the circulation via the lymphatic system. In
clinical conditions of increased capillary porosity, like sep-
sis, albumin and other proteins may reach the extravascu-
lar space and, consequently, πis rises and the flow of fluid
increases. The use of colloids for volume resuscitation has
been associated with increased need for renal replacement
therapy, worsening edema, and mortality [23]. This could
be due to progressive accumulation of colloidal molecules
in the interstitial space through the injured endothelium.
In this scenario, functional integrity of the lymphatic sys-
tem is essential to avoid edema formation [20]. Further-
more, since πiv opposes the fluid transcapillary flux but is
not able to reverse it, infusion of albumin or synthetic
Figure 2 Glycocalyx characteristics in normal endothelium (left) and during endothelial dysfunction (right). ETC, endothelial cleft.
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tion. This explains why albumin infusion, despite showing
a better ‘volemic’ effect, is not able to resolve the intersti-
tial edema in patients with sepsis [20,24]. In hypovolemic
states, the fall in Piv leads to a transient back-filtration of
fluid from the interstitial space in the intravascular space;
as a result, Piv progressively increases until filtration
stops. In sepsis, inflammatory injury to the glycocalyx
increases porosity of endothelium, and albumin can flow
through the ETCs; πiv increases and this further opposes
back-filtration of fluid and drives edema formation
[20]. Infusion of colloids or crystalloid to restore macro-
hemodynamics leads to a progressive increase in Piv that
further contributes to trans-capillary fluid escape and
interstitial edema. Therefore, the smallest possible volume
for plasma volume resuscitation should be used in order
to maintain normovolemia and simultaneously reduce the
risk of accumulation of interstitial fluid. In sepsis, where
porosity increases because of inflammation injury, colloid
molecules can flow in the interstitial space, thus increasing
πis. These observations may have clinical consequences.
Indeed, an interesting recent study on murine models by
Bark and colleagues [25] showed that, in conditions of in-
creased transcapillary flow like sepsis, the total volume of
colloids necessary to maintain normovolemia can be sig-
nificantly reduced when administered in slow infusion ra-
ther than as a bolus. This effect is probably linked to a
sharper increase in Piv that follows quick administration,
which in turn leads to greater transcapillary flow.Molecules of heparan sulfate link antithrombin III, pre-
venting microvascular thrombosis and contributing to
maintain microvascular patency. Moreover, the negative
charges of GAG side chains inhibit endothelial adhesion
of platelets and red cells, further contributing to maintain
microvascular anticoagulant properties and rheology. The
glycocalyx inhibits leukocyte adhesion to endothelium,
thus preventing migration of neutrophils in non-inflamed
tissues [7,26,27]. Indeed, integral glycocalyx has a geom-
etry that prevents the interaction between circulating leu-
kocytes and adhesion molecules or selectins. In case of
shedding, exposure of these molecules occurs, with subse-
quent endothelial-cellular interaction [15]. Heparan sul-
fate binds endothelial superoxide dismutase and xanthine
oxidoreductase [28-32]. Thus, intact glycocalyx protects
endothelial cells from oxidative stress [20,21].
Glycocalyx during inflammation
Localized or systemic inflammation leads to changes in
structure and physiology of glycocalyx, inducing endo-
thelial dysfunction (Figure 3). First and foremost, inflamma-
tion injury to glycocalyx is linked to increased paracellular
permeability and outflow of albumin/fluid in the interstitial
space through the ETCs [20]. Loss of anionic charges,
changes in geometry of the clefts, and direct endothelial
injury are responsible for this. Other observed changes in
glycocalyx function during inflammation include loss of
vascular tone with local blood pooling, degradation of
heparan sulfate leading to a shift toward a pro-coagulant
Figure 3 Modification of glycocalyx components during sepsis.
Representative light microphotograph of MAA (Maackia amurensis
agglutinin) lectin histochemistry in mesoceacum of sham-operated
(on the left side) and CLP (cecal ligation and puncture)-treated rats
(on the right side) at 7 hours after surgery. In blue, MAA reactivity
(indicating the presence of sialic acid linked α2,3 to galactose,
arrows) was intense in mesoceacal vessels of sham operated rats
(left side) and reduced in vessels of CPL rats (right side). Scale
bar = 25 μm. Courtesy of Eleonora Sgambati.
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pression of adhesion molecules with increased leukocyte
trafficking, and loss of antioxidative properties with pro-
gressive oxidative injury to the endothelium [15]. From an
evolutionary and adaptive perspective, this local inflamma-
tory response represents an active and structured response
to tissue invasion by micro-organisms or unrecognized
cells. In clinical syndromes of systemic inflammation, such
as sepsis, major surgery, trauma, ischemia/reperfusion, and
prolonged hyperglycemia, diffused and persistent alter-
ations of glycocalyx are linked to widespread endothelial
dysfunction, altered permeability, and impaired oxygen
and nutrient delivery to cells [8,33,34]. There is experi-
mental evidence that thickness and stiffness of endothelial
glycocalyx are reduced by lipopolysaccharide (LPS) or
tumor necrosis factor-alpha (TNF-α) exposure [35]. Clin-
ically, these alterations are linked to loss of vascular tone,
loss of albumin, hypovolemia, edema formation, and organ
dysfunction [7]. Persistence of these alterations is associ-
ated with poor clinical outcome even if macrohemody-
namic derangements have been corrected (see below).
Furthermore, owing to the ubiquitous nature of the glyco-
calyx, its alterations lead to clinically relevant effects of in-
flammation also distant from primarily involved organs
(that is, ‘organ cross-talk’ as in acute cardiorenal syn-
dromes, where inflammatory injury to kidneys leads to in-
flammatory damage to endothelium) [36,37].
Exposure to pro-inflammatory mediators such as inter-
leukin 1 (IL-1), IL-2, IL-6, TNF-α, and other molecules re-
leased during acute inflammation such as bradykinin,
thrombin, VEGF, and histamine results in endothelial acti-
vation and massive increase in glycocalyx expression of
endothelial leukocyte adhesion molecule 1, intercellular
adhesion molecule 1 (ICAM-1), and vascular cell adhesion
molecule 1 (VCAM-1). These proteins promote leukocyte
rolling, adherence, and migration, which initiate the
inflammatory damage to endothelium and tissues [10].Subsequent damage to endothelium promotes degrad-
ation and shedding of glycocalyx with progressive increase
in paracellular permeability. During this shedding process,
adhesion molecules are released and can be found in cir-
culating blood; thus, in patients with sepsis, circulating
levels of VCAM-1 and ICAM-1 parallel those of IL-6 [38];
this was more evident in patients with hyperglycemic sep-
sis, in which the inflammatory damage to endothelium
may be worsened by persistent hyperglycemia [39]. In an
experimental model of sepsis, high levels of TNF-α were
associated with reduced expression of syndecan 1 and al-
tered composition of hyaluronan and sialic acids [40].
Shedding of the glycocalyx and release of syndecans in the
circulation may also retain an adaptive function in limiting
the inflammatory damage mediated by TNF-α. Interaction
of syndecans with TNF-α leads to a structural rearrange-
ment of endothelial cells and loosening of intercellular
junctions; this greatly increases paracellular permeability,
further allowing extravasations of fluids, albumin, and sol-
utes [2]. It is known that VEGF induces angiogenesis and
markedly increases endothelial permeability [41]. Gram-
negative bacterial LPS increases VEGF-mRNA expression
in macrophages and induces release of VEGF by leuko-
cytes and platelets [42]. The kidneys are a major source of
VEGF production in humans, and it has been speculated
that VEGF may play some role in regulating the glomeru-
lar permeability to protein. The mechanisms of increased
vascular permeability by VEGF may involve stimulation of
collagenase production and proteolytic disruption of the
endothelial basement membrane [6,43]. Renal release of
VEGF during septic acute kidney injury may contribute to
distal organ endothelial damage (that is, organ ‘cross-talk’).
Therefore, it is important to underline that the urin-
ary microalbuminuria has been demonstrated to be a
reliable marker of sepsis-induced alterations of endothelial
barrier and changes in systemic paracellular permeability
[9,44-48]. Indeed, albuminuria greatly increased in an ex-
perimental model of sepsis in association with the afore-
mentioned observed structural changes of glycocalyx [40].
Oxidative stress plays a central role in inflammatory
injury to glycocalyx. In vitro, exposure of GAGs to react-
ive oxygen species derived from leukocytes (such as
superoxide anion and hydroxyl radicals) causes fragmen-
tation of GAGs with loss of some of its components
[49]. Degradation of glycocalyx will expose the endothe-
lial cells to oxidative damage, which has been linked to
increased porosity, and interstitial loss of albumin ob-
served in both severe sepsis and chronic conditions like
diabetes or hypertension [21,34].
In patients with sepsis, endothelial glycocalyx may be
affected by co-existing clinical conditions. Lipoprotein-
lipase controls the release of fatty acids to tissues and its
primary site of action is the luminal side of the endothelial
cell (glycocalyx) [21]; diet-induced hyperlipidemia produces
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teins in the sub-endothelial space [50]. Pro-inflammatory
cytokines locally released by perivascular adipocytes act
through a paracrine mechanism and independently con-
tribute to glycocalyx injury [51]. In contrast, glycocalyx in-
tegrity may be protective in atherosclerosis [52], whereas
in patients with heterozygous familial hypercholesterol-
emia, the overall volume of glycocalyx is decreased [53].
Both acute hyperglycemia and chronic hyperglycemia in-
duce shedding of the glycocalyx, contributing to endothe-
lia dysfunction and loss of albumin [54]. It was found that,
compared with healthy individuals, patients with diabetes
mellitus type 1 or type 2 have a reduced volume of glyco-
calyx [55]. It is reasonable to argue that acute systemic in-
flammation observed in sepsis may act in combination
with chronic hyperglycemia, insulin resistance, oxidative
stress, or activation of the renin-angiotensin system to
amplify the already existing injury to glycocalyx. This
could make it difficult to compare septic patients with dif-
ferent co-morbidities. The extent of this phenomenon is
still unclear, and disease-specific markers of glycocalyx in-
jury have not been described.
Markers of glycocalyx degradation
Circulating levels of syndecan 1 are related to endothelial
damage and glycocalyx degradation and correlate with
serum levels of inflammatory cytokines [56]. They are also
associated with coagulopathy and increased mortality in
trauma patients [57]. Since levels of syndecans may be
higher in patients with sepsis than in surgical patients, they
are thought to be a biomarker of more extensive damage of
the glycocalyx since they are core proteins [38,58]. Endocan
is another component of glycocalyx that can be released
in response to TNF-α and IL-1 and act as a biomarker in
patients with sepsis. Circulating levels of endocan have
been shown to correlate with severity of sepsis [4,59], and
high serum levels of endocan were associated with the de-
velopment of acute lung injury after major trauma [60].
As such, endocan is considered a promising biomarker of
endothelial dysfuncion in sepsis.
The increase of microalbuminuria is a consequence of in-
creased permeability due to inflammatory injury to glom-
erular endothelium which is frequently observed in clinical
practice and experimental models of septic-related acute
kidney injury (see above) [43]. In individual patients, the
microalbuminuria-urinary creatinine ratio (MACR) corre-
lates with severity scores such as the Surgical Stress Score
[61], the Injury Severity Score [62], Acute Physiological
and Chronic Health Evaluation II [63], the Sequential
Organ Function Assessment [64], and the Simplified Acute
Physiology Score II, and with duration of mechanical
ventilation and partial pressure arterial oxygen/fraction
of inspired oxygen ratio [65]. In patients with sepsis,
MACR levels increase earlier than C-reactive proteinand procalcitonin [66]. Indeed, microalbuminuria itself
may be considered a marker of sepsis severity [44].
Angiopoietins (Angs) are a novel class of angiogenetic
growth factors that have recently been recognized to play
a substantial role in the inflammatory process [67]. Ang-1
promotes structural stability of blood vessels, whereas
Ang-2 promotes vascular destabilization and permeability
[67]. Ang-1 and -2 are reciprocally antagonistic factors in-
volved in important intracellular pathways. In critically ill
patients, the release of Ang-2 directly reflects vascular bar-
rier breakdown [68]. It has been demonstrated that Ang-2
is increased in septic shock and that its increase is related
to unfavorable outcome [69], although routine measure-
ment of circulating Ang-2 is not clinically feasible.
Therapeutic strategies
Despite the growing evidence that glycocalyx is extensively
involved in sepsis-related altered vascular permeability,
strategies aiming at correcting these alterations failed to
show clear clinical benefit [3]. Corticosteroids could de-
crease the inflammatory injury in systemic sepsis and re-
duce inflammatory damage to endothelium [48]. Indeed,
there is some evidence that their use is associated with re-
duced microalbuminuria; a protective effect on glomerular
glycocalyx may be postulated [6,44]. Indeed, low-dose
hydrocortisone improved MACR in patients with severe
sepsis [44]. Corticosteroids are known to inhibit cytokine
synthesis, in particular TNF-α. Since TNF-α leads to rear-
rangements of endothelial cells (see above), reduced release
of TNF-α could preserve the integrity of the endothelium
[6]. Despite this experimental evidence, the clinical utility
of corticosteroids in sepsis is still debated [70,71]. Anti-
coagulant molecules such as antithrombin or activated
protein C may exert their effects by preserving glycocalyx
integrity [72]. However, both molecules failed to improve
outcome of patients with septic shock [7]. The use of anti-
oxidant therapies may help to preserve integrity of
glycocalyx. One study showed the efficacy of an infu-
sion of N-acetylcysteine in preventing hyperglycemia-
induced shedding of glycocalyx [73]. This supports the role
of oxidative stress in the impairment of the glycocalyx and
in endothelial dysfunction. However, definitive evidence of
clinical utility of antioxidant in sepsis is still lacking. Tight
glycemic control may reduce glycocalyx shedding in sepsis
and preserve endothelial function [21,73]. This potential
positive effect of glycemic control has been confirmed also
for chronic hyperglycemia [39,74].
Conclusions
Endothelial dysfunction and glycocalyx degradation are
key features of sepsis. In severe sepsis and septic shock,
they cause alterations of macro- and micro-circulation,
alter organ perfusion, and contribute to cellular hypoxia,
which all lead to organ dysfunction. Inflammatory-
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number of specific clinical effects of sepsis, including
acute kidney injury, respiratory failure, and hepatic dys-
function. Markers of glycocalyx degradation, such as
microalbuminuria or circulating levels of endocan or
selectins, are promisingly employed as markers of sever-
ity of sepsis. Some of the proposed therapies of sepsis,
including corticosteroids, may counteract alterations of
endothelium and glycocalyx. Their actual clinical efficacy
still needs to be proven.
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